Edition:
United States

Epizyme Inc (EPZM.OQ)

EPZM.OQ on NASDAQ Stock Exchange Global Select Market

15.85USD
20 Apr 2018
Change (% chg)

$-0.20 (-1.25%)
Prev Close
$16.05
Open
$16.00
Day's High
$16.20
Day's Low
$15.65
Volume
71,566
Avg. Vol
123,285
52-wk High
$21.35
52-wk Low
$9.35

Chart for

About

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of... (more)

Overall

Beta: 1.95
Market Cap(Mil.): $1,101.29
Shares Outstanding(Mil.): 69.48
Dividend: --
Yield (%): --

Financials

  EPZM.OQ Industry Sector
P/E (TTM): -- 188.22 33.60
EPS (TTM): -1.30 -- --
ROI: -29.35 -0.74 13.19
ROE: -33.27 -2.80 15.00

BRIEF-Epizyme Inc Files For Potential Mixed Shelf, Size Not Disclosed

* EPIZYME INC FILES FOR POTENTIAL MIXED SHELF; SIZE NOT DISCLOSED - SEC FILING Source text: (https://bit.ly/2q8HM38) Further company coverage:

Apr 05 2018

BRIEF-Epizyme Q4 Loss Per Share $0.52

* EPIZYME REPORTS FOURTH QUARTER AND FULL YEAR 2017 OPERATING RESULTS AND 2018 MILESTONES

Mar 13 2018

Competitors

  Price Chg
Eisai Co., Ltd (4523.T) ¥7,074 -19.00
Novartis AG (NOVN.S) CHF76.08 -1.20
GlaxoSmithKline plc (GSK.L) 1,430.00 +22.60
Celgene Corporation (CELG.OQ) $88.95 -0.67

Earnings vs. Estimates